Literature DB >> 25281471

Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy: possible involvement of periostin.

Yoshiyuki Kobayashi1, Shigeo Yoshida1, Takahito Nakama1, Yedi Zhou1, Keijiro Ishikawa1, Ryoichi Arita1, Shintaro Nakao1, Masanori Miyazaki1, Yukio Sassa2, Yuji Oshima1, Kenji Izuhara3, Toshihiro Kono4, Tatsuro Ishibashi1.   

Abstract

AIM: To determine whether CD163, a specific marker for M2 macrophages, is involved in the formation of preretinal fibrovascular membranes (FVMs) present in eyes with proliferative diabetic retinopathy (PDR).
METHODS: We measured the levels of soluble (s)CD163, periostin and vascular endothelial growth factor by sandwich ELISA in vitreous samples from 74 eyes of 62 patients with PDR, 20 eyes of 18 patients with proliferative vitreoretinopathy, and 56 eyes of 54 patients with non-diabetic ocular diseases (control group). Immunohistochemical analyses were performed to determine the expressions of CD68, CD163 and periostin in the surgically resected FVMs and idiopathic epiretinal membranes (ERMs).
RESULTS: The concentrations of sCD163 and periostin in the vitreous were significantly higher in patients with PDR than in non-diabetic controls (p<0.0001). There was a strong correlation between the vitreous concentrations of sCD163 and periostin. The mean vitreous level of sCD163 was significantly higher in eyes with FVMs than in those without FVMs (epicentre only). The number and percentage of CD163+ macrophages were significantly higher in the FVMs than in the idiopathic ERMs. Immunohistochemical analysis showed co-localisation of CD163 and periostin in FVM cells.
CONCLUSIONS: These findings indicate that the overexpression of CD163 by macrophages may be involved in the development of FVMs partly through periostin production. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Retina; Vitreous

Mesh:

Substances:

Year:  2014        PMID: 25281471     DOI: 10.1136/bjophthalmol-2014-305321

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

Review 1.  Periostin in vitreoretinal diseases.

Authors:  Shigeo Yoshida; Takahito Nakama; Keijiro Ishikawa; Shintaro Nakao; Koh-Hei Sonoda; Tatsuro Ishibashi
Journal:  Cell Mol Life Sci       Date:  2017-09-14       Impact factor: 9.261

Review 2.  Diverse roles of macrophages in intraocular neovascular diseases: a review.

Authors:  Ye-Di Zhou; Shigeo Yoshida; Ying-Qian Peng; Yoshiyuki Kobayashi; Lu-Si Zhang; Luo-Sheng Tang
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

Review 3.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

4.  Interleukin-19 Promotes Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.

Authors:  Jingling Zou; Wei Tan; Bingyan Li; Zicong Wang; Yun Li; Jun Zeng; Bing Jiang; Shigeo Yoshida; Yedi Zhou
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-07-08       Impact factor: 4.925

5.  Tenascin-C secreted by transdifferentiated retinal pigment epithelial cells promotes choroidal neovascularization via integrin αV.

Authors:  Yoshiyuki Kobayashi; Shigeo Yoshida; Yedi Zhou; Takahito Nakama; Keijiro Ishikawa; Yuki Kubo; Mitsuru Arima; Shintaro Nakao; Toshio Hisatomi; Yasuhiro Ikeda; Akira Matsuda; Koh-Hei Sonoda; Tatsuro Ishibashi
Journal:  Lab Invest       Date:  2016-09-26       Impact factor: 5.662

6.  APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2.

Authors:  Chunhua Jiao; Dean Eliott; Christine Spee; Shikun He; Kai Wang; Robert F Mullins; David R Hinton; Elliott H Sohn
Journal:  Retina       Date:  2019-02       Impact factor: 4.256

7.  Assessment of circulating fibrotic proteins (periostin and tenascin -C) In Type 2 diabetes mellitus patients with and without retinopathy.

Authors:  A Indumathi; Gandhipuram Periyaswamy Senthilkumar; Kuppuswamy Jayashree; K Ramesh Babu
Journal:  Endocrine       Date:  2022-03-10       Impact factor: 3.925

Review 8.  Periostin: its role in asthma and its potential as a diagnostic or therapeutic target.

Authors:  Wei Li; Peng Gao; Yue Zhi; Wei Xu; Yanfeng Wu; Jinzhi Yin; Jie Zhang
Journal:  Respir Res       Date:  2015-05-17

9.  Interleukin-12 inhibits pathological neovascularization in mouse model of oxygen-induced retinopathy.

Authors:  Yedi Zhou; Shigeo Yoshida; Yuki Kubo; Yoshiyuki Kobayashi; Takahito Nakama; Muneo Yamaguchi; Keijiro Ishikawa; Shintaro Nakao; Yasuhiro Ikeda; Tatsuro Ishibashi; Koh-Hei Sonoda
Journal:  Sci Rep       Date:  2016-06-17       Impact factor: 4.379

10.  Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy.

Authors:  Yoshiyuki Kobayashi; Shigeo Yoshida; Yedi Zhou; Takahito Nakama; Keijiro Ishikawa; Mitsuru Arima; Shintaro Nakao; Yukio Sassa; Atsunobu Takeda; Toshio Hisatomi; Yasuhiro Ikeda; Akira Matsuda; Koh-Hei Sonoda; Tatsuro Ishibashi
Journal:  Mol Vis       Date:  2016-04-30       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.